These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37862458)

  • 1. Letter to the Editor: Benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect or residual confounding?
    Dongelmans EJ; Sonneveld MJ; Janssen HLA
    Hepatology; 2024 Mar; 79(3):E95-E96. PubMed ID: 37862458
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply: Benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect, or residual confounding?
    Liaw YF; Jeng WJ; Chien RN
    Hepatology; 2024 Mar; 79(3):E97-E98. PubMed ID: 37862454
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Deng R; Wang Z; Liu Y; Sun J
    Hepatology; 2024 Apr; 79(4):E107-E108. PubMed ID: 37906598
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma.
    Liu SY; Yuan C; Tong XM
    J Hepatol; 2022 Nov; 77(5):1471-1472. PubMed ID: 35863489
    [No Abstract]   [Full Text] [Related]  

  • 5. Quantitative Hepatitis B Surface Antigen, the Trustworthy Biomarker for Functional Cure of Chronic Hepatitis B.
    Choi J
    Gut Liver; 2023 Mar; 17(2):179-180. PubMed ID: 36918269
    [No Abstract]   [Full Text] [Related]  

  • 6. Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring.
    Tsai YN; Wu JL; Hsu YC
    Clin Mol Hepatol; 2024 Apr; 30(2):293-296. PubMed ID: 38373419
    [No Abstract]   [Full Text] [Related]  

  • 7. KASL clinical practice guidelines for management of chronic hepatitis B.
    Korean Association for the Study of the Liver (KASL)
    Clin Mol Hepatol; 2019 Jun; 25(2):93-159. PubMed ID: 31185710
    [No Abstract]   [Full Text] [Related]  

  • 8. [Research progress of biomarkers of hepatitis B virus and clinical significance].
    Wang X; Tang X; Han N; Tang H
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2023 Dec; 40(6):1242-1248. PubMed ID: 38151949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letter: improved alanine aminotransferase level in patients with chronic hepatitis B without cirrhosis and low viral load treated with nucleotide/nucleoside analogues.
    Jang TY
    Aliment Pharmacol Ther; 2023 Mar; 57(5):587-588. PubMed ID: 36786461
    [No Abstract]   [Full Text] [Related]  

  • 10. [Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis].
    Xu Y; Wang JB; Xu J; Jiao J; Zhang YG; Ji SW; Zhao P; Guo HH; Li Y; Zhou CY
    Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):109-12. PubMed ID: 20196949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severity of Hepatitis B Relapse After Cessation of Nucleos(t)ide Analog: Need a Closer Look!
    Jindal A
    Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1885-1886. PubMed ID: 34508869
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical features of acute hepatitis E super-infections on chronic hepatitis B.
    Chen C; Zhang SY; Zhang DD; Li XY; Zhang YL; Li WX; Yan JJ; Wang M; Xun JN; Lu C; Ling Y; Huang YX; Chen L
    World J Gastroenterol; 2016 Dec; 22(47):10388-10397. PubMed ID: 28058019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting liver metabolism: a pathway to cure hepatitis B virus?
    Ajoyan H; Douglas MW; Tu T
    Expert Rev Gastroenterol Hepatol; 2023; 17(7):645-647. PubMed ID: 37318059
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
    Jeng WJ; Chien RN; Liaw YF
    Hepatology; 2024 May; 79(5):E134-E135. PubMed ID: 38150032
    [No Abstract]   [Full Text] [Related]  

  • 15. [Ten-year changes in clinical characteristics and antiviral treatment patterns of chronic hepatitis B in China: a CR-HepB-based real-world study].
    Xu XQ; Wang H; Shan S; You H; Nan YM; Xu XY; Duan ZP; Wei L; Hou JL; Zhuang H; Jia JD; Kong YY;
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jul; 31(7):698-704. PubMed ID: 37580251
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatitis B virus infection--natural history and clinical consequences.
    Ganem D; Prince AM
    N Engl J Med; 2004 Mar; 350(11):1118-29. PubMed ID: 15014185
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatitis B virus liver decompensation: antiviral therapy for all.
    Tiwari A; Mehrotra M; Hasan A; Agarwal J; Singh GK
    J Gastroenterol Hepatol; 2023 May; 38(5):833-834. PubMed ID: 36999212
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of serum Golgi protein 73 for screening chronic hepatitis B virus infection patients needing antiviral therapy in the community.
    Duan J; Wen X; Wang H; Chen W; Gao P; Yuan Q; Zheng H; Liu Y; Wu J; Wang J; Yao M; Lu F
    Chin Med J (Engl); 2022 Nov; 135(22):2741-2743. PubMed ID: 36574219
    [No Abstract]   [Full Text] [Related]  

  • 19. [Imperatives to strengthen HBsAg screening and expand antiviral therapy indications on hepatitis B among the general population].
    Chen EQ
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):646-648. PubMed ID: 37400392
    [No Abstract]   [Full Text] [Related]  

  • 20. Genomics on the road to functional cure of hepatitis B.
    Balagopal A; Thomas DL
    J Hepatol; 2024 Jan; 80(1):6-7. PubMed ID: 37984710
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.